Linking the gap from development to robust manufacturing
The complex journey of bringing a biologic to market – part 3 It is a critical shift for companies when transitioning from early development to clinical production, where you transfer ...
The Nordics are dancing on
What’s hot and what’s not in ATMP? Insights from service providers, investors, and academics at the 2024 BIO-Europe conference in Stockholm.
BIO-Europe celebrated its 30th anniversary in Stockholm, Sweden, on November 4–6, 2024, bringing together over 5,000 delegates from around the world.
Post-pandemic, life science companies face funding challenges, emphasizing the need for solid data over visions. The Nordic region, though small individually, thrives through innovation and collaboration, with promising developments in manufacturing and funding strategies. Trends in CGT, such as diversification beyond mRNA and integrating AI for efficiency, are discussed in this article. Challenges in manufacturing and affordability remain critical. Despite hurdles, optimism persists, with Nordic companies leveraging global partnerships to remain a hotspot for CGT innovation.
Read the full conference report by Helena Strigård, Roger Lias and NorthX Biologics’ very own Eva-Karin Gidlund, in Cell & Gene Therapy Insights here.
About NorthX Biologics AB
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn